Why did RAC.AX stock jump today?

RAC.AX stock rose on 19 Mar 2026 on heavy intraday volume and investor interest tied to clinical and sector catalysts. No single large corporate announcement was published; traders appear to be pricing expected trial developments and speculative flows.

What valuation metrics are important for RAC.AX stock?

Key metrics for RAC.AX stock include EPS **-0.05**, PE **-47.60**, PB **17.76**, cash per share **A$0.12**, and market cap **A$432.50M**. These reflect clinical-stage valuation and higher outcome-driven risk.

What is Meyka AI's short-term forecast for RAC.AX stock?

Meyka AI's short-term model gives a monthly figure of **A$2.31**, a quarterly target of **A$3.18**, and a one-year projection of **A$3.39**. Forecasts are model-based projections and not guarantees.

How should investors weigh risks in RAC.AX stock?

Investors must weigh binary clinical outcomes, negative earnings, and premium valuation multiples. Positive trial news could re-rate RAC.AX stock, while setbacks may trigger sharp declines given current multiples and R&D reliance.

AU Stocks

RAC.AX Race Oncology up 27.78% intraday 19 Mar 2026: catalyst-driven move to monitor

ByHuzaifa Zahoor March 19, 2026March 19, 2026

RAC.AX stock jumped 27.78% to A$2.76 intraday on 19 Mar 2026, making Race Oncology Limited a top gainer on the ASX. Volume surged to 307,283 shares versus an average of 164,099, signalling fresh buying interest. The move came without a large corporate transaction announced on the company site, so traders appear to be pricing clinical and sector catalysts into the stock. We track how these intraday flows connect to clinical timelines, valuation metrics, and Meyka AI’s short and medium-term forecasts.